Experimental combo targets Hard-to-Treat colorectal liver metastases

NCT ID NCT07357220

Not yet recruiting Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of two experimental treatments—AK112 (given through a vein) and VG2025 (injected directly into liver tumors)—in 72 adults with advanced colorectal cancer that has spread to the liver and hasn't responded to prior therapy. The goal is to see if the combo is safe and can shrink tumors. It's an early-phase trial, so the main focus is on safety and finding the right dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
AK112 (a drug) and VG2025 (a biologic injected into the tumor)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced colorectal cancer that has spread to the liver and hasn't responded to standard therapy.
What could go wrong
This is an early-phase trial with only 72 participants, so results may not apply to everyone. The combination could cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER WITH HEPATIC METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • The First Affiliated Hospital, Zhejiang University School of Medicine,No. 79, Qingchun Road, Shangcheng District, Hangzhou City, Zhejiang Province

    Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.